Paper22160036
Genetic and epigenetic complexity in myeloproliferative neoplasms.
Cross NC. Hematology Am Soc Hematol Educ Program, 2011. Cited by 89 papers, by iCite.
Cite this record
ConductScience Library. Genetic and epigenetic complexity in myeloproliferative neoplasms. Papers, record 22160036. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22160036
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bone Marrow Neoplasms | Major topic |
| Epigenesis, Genetic | Major topic |
| Myeloproliferative Disorders | Major topic |
| Genetic Predisposition to Disease | |
| Genomic Instability | |
| Humans | |
| Janus Kinase 2 |
Source PubMed
Cited by44
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 89 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38585044 | Laboratory-developed Droplet Digital PCR Assay for Quantification of the JAK2 V617F Mutation. | Glob Med Genet | 2024 | https://conductscience.org/library/papers/38585044 | PubMed |
| 38310350 | Detecting Multiple Driver Mutations in a Patient with Essential Thrombocythemia. | Am J Case Rep | 2024 | https://conductscience.org/library/papers/38310350 | PubMed |
| 34631089 | Hereditary hemochromatosis and JAK2-positive polycythemia vera. | Clin Case Rep | 2021 | https://conductscience.org/library/papers/34631089 | PubMed |
| 33639674 | Frequency of Zygosity in Jak-2 Positive Patients with Polycythemia Vera-Pakistan's Perspective. | Asian Pac J Cancer Prev | 2021 | https://conductscience.org/library/papers/33639674 | PubMed |
| 31106152 | The Role of New Technologies in Myeloproliferative Neoplasms. | Front Oncol | 2019 | https://conductscience.org/library/papers/31106152 | PubMed |
| 30899467 | When hemolysis masks polycythemia vera. | Clin Case Rep | 2019 | https://conductscience.org/library/papers/30899467 | PubMed |
| 30828140 | Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes: Molecular Pathogenetic Mechanisms and Their Implications. | Indian J Hematol Blood Transfus | 2019 | https://conductscience.org/library/papers/30828140 | PubMed |
| 30765477 | SDF1α-induced chemotaxis of JAK2-V617F-positive cells is dependent on Bruton tyrosine kinase and its downstream targets PI3K/AKT, PLCγ1 and RhoA. | Haematologica | 2019 | https://conductscience.org/library/papers/30765477 | PubMed |
| 30056580 | A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs. | Ann Hematol | 2018 | https://conductscience.org/library/papers/30056580 | PubMed |
| 29650953 | HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis. | Nat Commun | 2018 | https://conductscience.org/library/papers/29650953 | PubMed |
| 29562644 | Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis. | Int J Mol Sci | 2018 | https://conductscience.org/library/papers/29562644 | PubMed |
| 29235894 | Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia. | Future Oncol | 2018 | https://conductscience.org/library/papers/29235894 | PubMed |
| 29085634 | Prevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population. | Biomed Rep | 2017 | https://conductscience.org/library/papers/29085634 | PubMed |
| 28859112 | Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development. | PLoS One | 2017 | https://conductscience.org/library/papers/28859112 | PubMed |
| 28827411 | Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. | Blood | 2017 | https://conductscience.org/library/papers/28827411 | PubMed |
| 27756071 | Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review. | Med Princ Pract | 2016 | https://conductscience.org/library/papers/27756071 | PubMed |
| 27648344 | Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors. | J Adv Pract Oncol | 2015 | https://conductscience.org/library/papers/27648344 | PubMed |
| 27570458 | Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned. | Onco Targets Ther | 2016 | https://conductscience.org/library/papers/27570458 | PubMed |
| 27567907 | Ruxolitinib dose management as a key to long-term treatment success. | Int J Hematol | 2016 | https://conductscience.org/library/papers/27567907 | PubMed |
| 27341078 | A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells. | Blood Cancer J | 2016 | https://conductscience.org/library/papers/27341078 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ABL1 | 25 | PubTator's text mining | https://conductscience.org/library/genes/25 | NCBI Gene |
| JAK2 | 3717 | PubTator's text mining | https://conductscience.org/library/genes/3717 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/22160036
GET https://conductscience.org/api/papers/v1/22160036/cited_by?page=2